Summary of efficacy at week 24 and week 52 among randomised patients by number of prior biological anti-TNF exposure (1 vs >1)
| Placebo→UST 45 mg | UST 45 mg | UST 90 mg | Combined UST | |
|---|---|---|---|---|
| Week 24 (N) | 62 | 60 | 58 | 118 |
| ACR20 response by number of prior biological anti-TNF agents | ||||
| 1 prior agent | 3/30 (10.0) | 8/23 (34.8) | 10/28 (35.7) | 18/51 (35.3) |
| >1 prior agent | 6/32 (18.8) | 14/37 (37.8) | 10/30 (33.3) | 24/67 (35.8) |
| PASI75 response by number of prior biological anti-TNF agents* | ||||
| 1 prior agent | 0/27 (0.0) | 7/15 (46.7) | 12/21 (57.1) | 19/36 (52.8) |
| >1 prior agent | 1/23 (4.3) | 13/29 (44.8) | 8/20 (40.0) | 21/49 (42.9) |
| HAQ-DI change from baseline by number of prior biological anti-TNF agents | ||||
| 1 prior agent (n) | 30 0.00 (0.00 to 0.25) | 23 −0.13 (−0.38 to 0.00) | 28 −0.25 (−0.50 to 0.00) | 51 −0.25 (−0.50 to 0.00) |
| >1 prior agent (n) | 32 0.00 (−0.13 to 0.00) | 37 −0.13 (−0.38 to 0.00) | 30 0.00 (−0.38 to 0.00) | 67 −0.13 (−0.38 to 0.00) |
| Week 52 (N) | 43† | 60 | 58 | 118 |
| ACR20 response by number of prior biological anti-TNF agents | ||||
| 1 prior agent | 12/22 (54.5) | 11/21 (52.4) | 14/28 (50.0) | 25/49 (51.0) |
| >1 prior agent | 4/18 (22.2) | 9/33 (27.3) | 8/26 (30.8) | 17/59 (28.8) |
| PASI75 response by number of prior biological anti-TNF agents* | ||||
| 1 prior agent | 8/20 (40.0) | 5/13 (38.5) | 12/21 (57.1) | 17/34 (50.0) |
| >1 prior agent | 5/10 (50.0) | 8/23 (34.8) | 8/19 (42.1) | 16/42 (38.1) |
| HAQ-DI change from baseline by number of prior biological anti-TNF agents | ||||
| 1 prior agent (n) | 22 0.00 (−0.13 to 0.13) | 21 −0.25 (−0.50 to 0.00) | 28 −0.19 (−0.50 to 0.00) | 49 −0.25 (−0.50 to 0.00) |
| >1 prior agent (n) | 18 0.00 (−0.13 to 0.13) | 33 −0.13 (−0.38 to 0.00) | 26 0.00 (−0.50 to 0.00) | 59 0.00 (−0.50 to 0.00) |
Data are reported as n (%), n/N (%) or median (IQR).
*Among patient with ≥3% BSA psoriasis skin involvement at baseline.
†Excludes patients who did not receive ustekinumab.
ACR, American College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI, Psoriasis Area and Severity Index; TNF, tumour necrosis factor-α; UST, ustekinumab.